Garden Grove, California, March 06, 2017 -- The Graystone Company (OTC: GYST) announced today that the company has begun placing all of its time, energy and resources into the Cannabis Industry.
Company spokesperson Alfred Mendoza stated, “The timing of this change in direction could not be better for both the shareholders and company alike. As for the company progress to date, we have leased a space for our first cannabis related business in Garden Grove, California. We have filed the necessary paperwork for the collective and have secured vehicles and hired drivers. In very short order, The Graystone Company will begin operating its first of many Cannabis Delivery services in the great state of California. As far as our shareholders are concerned, our current share structure is stable with only 122,391,521 shares outstanding and 25,248,928 in the float.”
The Graystone Company, Inc. is in the process of building out a scalable business operation in the Cannabis Industry that will include multiple Cannabis Delivery Services and Dispensaries. The first Delivery Service begins operations in March 2017.
Mr. Mendoza went on to say, “We have built out a sizable database of cannabis providers and end users over past several months. We are contracting with Weedmaps.com next week. As we begin operations with Cannabis Delivery, we do so with one eye on a move into Dispensary Operations as well. We could not be more excited about our new direction. We are ready to hit the ground running and we want our shareholders to know that we have their best interests in mind and will keep the investment community updated on a frequent basis going forward as it pertains to our overall progress.”
Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual and interim reports.
Contact: Graystone Co. Phone: 1-347-688-9003 Email: [email protected]


Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 



